Penghua STAR Market Healthcare ETF Surges Over 4%, Capital, Policy, and Fundamentals Converge to Ignite Pharma Sector Rally

Industry
โดย Eastmoney·Read original
Summary · why it matters

The pharmaceutical sector saw a broad-based rally, with the Penghua STAR Market Healthcare ETF climbing 4.12% to 1.12 yuan. The Shanghai STAR Market Biomedical Index it tracks surged 3.66%. Institutions note that this rebound is a value revaluation driven by a triple resonance of capital, policy, and fundamentals. The core driver is a shift of funds from the previously high-flying tech sector into innovative drugs, which have better prospects and are trading near bottom levels. On the policy front, the state continues to increase support for the entire innovative drug industry chain. On the fundamentals side, overseas business development deals keep materializing, with innovative drug BD deal values in the first half of 2026 hitting a new high despite the high base in the same period of 2025. Institutions believe that there is strong willingness for further capital allocation, and the pace of overseas commercialization is clear. Innovative drugs are the core investment theme for the pharmaceutical sector over the next three to five years, and this rebound is merely an initial warm-up. As of June 30, 2026, the top ten constituents of the Shanghai STAR Market Biomedical Index accounted for 51.84% of the total weight, including United Imaging Healthcare, Allist Pharmaceuticals, and BeiGene.

Impact on stocks 4

Others▲ · 4 stocks
BeiGene Ltd.
688235
▲ PositiveDemandrelevance

Innovative drug BD deal values hit new high in H1 2026, indicating strong demand for BeiGene's products.

© 2026 MarketDXNews